Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
about
Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingTargeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapyMonitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonator-based oximetry.γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.Replication stress and cancer: it takes two to tango.Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cellsThe Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagyMolecular Pathways: Targeting ATR in Cancer TherapyDNA replication stress and cancer: cause or cure?Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities.NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations.Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer CellsCell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitorSuppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.ATR/CHK1 inhibitors and cancer therapy.BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy.Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro-in vivo correlation.LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.Highlights on molecular targets for radiosensitization of breast cancer cells: Current research status and prospects
P2860
Q26863501-36687219-0189-45EA-B98C-CBED1D32E81FQ34654741-555475DA-A3BE-4F96-B2B2-2036EB9A9301Q35039916-8DA3D7EC-FA11-40A2-A9A3-DBE552759A0EQ35201518-91631D88-7F7C-4817-9E51-44CECCC5EAE8Q35537834-A7BE8D66-5DFC-43D9-8030-79893426C757Q36094941-2ED3C209-0561-40AF-8E58-3EC72BE9956CQ36546469-ED604046-A14F-48A5-B21B-411C1B31CB98Q36738836-8059C486-84C0-443B-AD2A-26E8AA08EC78Q36863266-A67BB4AF-46DF-4AB5-B873-090EE93BFC38Q36931593-B3C13BB1-14B2-42BE-89D7-25581BD43869Q37641736-ACC10948-E0F8-44C1-9E64-8066458974B3Q37744731-4B9F81A9-F68F-4A06-A005-514DB30603B9Q38585436-3504F8C3-303B-4051-A34B-6D4F85ADFE9CQ38652528-678261F3-F020-4632-A1D8-1C5176688B37Q39191984-56A6B65A-8922-4FBC-BC44-CF931D25D20FQ41342397-D4FCF71D-7137-4D3A-BECB-61AB5D0994F0Q41470356-775049C0-0429-46AB-A923-50ED7E4497A4Q41838038-06B14F10-DD02-4022-8E0B-2012A12A4740Q43973311-C21EFA2F-85EF-46CE-A94E-6C1DA28223E8Q47130816-661F0CDC-8287-40A1-8439-A1575D30286EQ47622968-915E1667-CB05-41D4-9EED-11ED3E11AEBEQ47660928-38C7D67D-A392-4605-B830-AEB7F4BA4BA8Q50789493-F7F50DC6-FE05-4F40-B8CC-2D5350D6C1AEQ53465288-1BCF1BAD-653D-44D2-94BE-DAA6C6BE3638Q55035826-AC7F9BDD-578A-4327-8E1B-8936E2B9E995Q57111986-3A3B050A-84A7-4B19-AF84-872B3DB85B69
P2860
Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Sensitization of human cancer ...... schedule in vitro and in vivo.
@ast
Sensitization of human cancer ...... schedule in vitro and in vivo.
@en
type
label
Sensitization of human cancer ...... schedule in vitro and in vivo.
@ast
Sensitization of human cancer ...... schedule in vitro and in vivo.
@en
prefLabel
Sensitization of human cancer ...... schedule in vitro and in vivo.
@ast
Sensitization of human cancer ...... schedule in vitro and in vivo.
@en
P2093
P2860
P356
P1433
P1476
Sensitization of human cancer ...... schedule in vitro and in vivo.
@en
P2093
Alan Eastman
Huagang Hou
Injae Chung
Nadeem Khan
Ruth Thompson
Ryan Montano
P2860
P2888
P356
10.1186/1471-2407-13-604
P407
P577
2013-12-21T00:00:00Z
P5875
P6179
1028854168